Related Experiment Video
Updated: Dec 29, 2025
04:36
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
767
Current Approaches to Transplantation for FLT3-ITD AML
Bradley D Hunter1, Yi-Bin Chen2
1Blood and Marrow Transplant Program, Intermountain Healthcare, Salt Lake City, UT, USA.
Current Hematologic Malignancy Reports
|February 9, 2020
Summary
FLT3 TKIs and HCT have dramatically improved outcomes for FLT3-ITD AML. This review covers current standards of care, relapsed/refractory disease management, and ongoing research for FLT3-mutated acute myeloid leukemia.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- FLT3-ITD mutations are prevalent in acute myeloid leukemia (AML).
- Historically, FLT3-ITD AML is associated with a poor prognosis.
- Recent advancements have significantly improved patient outcomes.
Purpose of the Study:
- To review the standard of care for FLT3-ITD AML incorporating FLT3 Tyrosine Kinase Inhibitors (TKIs) and Hematopoietic Cell Transplantation (HCT).
- To outline an approach for managing relapsed/refractory FLT3-ITD AML.
- To discuss ongoing research and challenges in the field.
Main Methods:
- Literature review of current standards of care.
- Discussion of therapeutic strategies for FLT3-ITD AML.
- Exploration of relapse mechanisms and resistance to FLT3 inhibition.
Main Results:
- The integration of FLT3 TKIs and HCT has led to improved remission rates and overall survival.
- Minimal Residual Disease (MRD) assessment plays a crucial role in FLT3-ITD AML management.
- Current clinical trials are addressing optimal therapy sequencing and overcoming resistance.
Conclusions:
- FLT3 TKIs and HCT represent a significant advancement in FLT3-ITD AML treatment.
- Effective management of relapsed/refractory disease is critical.
- Further research is needed to optimize therapy and address resistance mechanisms.
